25 May 2013
Keywords: first, treatment, ph, ii, cytofab, trial, program
Article | 28 January 2008
UK-based Protherics says that Anglo-Swedish drug major AstraZeneca has treated the first patient in its expanded Phase II program of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 January 2008
24 May 2013
© 2013 thepharmaletter.com